Replies to post #13442 on RespireRx Pharmaceuticals Inc (fka RSPI)

[Aiming4]

Neuro - I trust your impressions since you've met Coleman and I'm glad to hear that the purchase he just made carries more weight than I would have guessed.

From his bio, I would have guessed that he has done very well financially... that is unless he's a unreformed bio-gambler, as Gfp has aptly labeled most of us here. :^)

James H. Coleman

Senior Vice President, Business Development

Mr. Coleman became Senior Vice President of Business Development in May 2000. Prior to joining Cortex, Mr. Coleman was President and Managing Partner of Diversified Healthcare Management, LLC (DHM), a biopharmaceutical consulting firm that he founded in 1997 in Irvine, CA. Cortex was a client of DHM for the year prior to his joining the company. Mr. Coleman brings to Cortex over 30 years of combined CNS pharmaceutical and biopharmaceutical experience at The Upjohn Company, Pharmacia & Upjohn, Inc., and CoCensys where he acquired extensive management and operational expertise in corporate partnering, global strategic CNS marketing, clinical psychopharmacological research and sales. Mr. Coleman, designed and managed the worldwide panic disorder research program that resulted in the first FDA and other offshore regulatory approvals that established Xanax® as the standard treatment for panic disorder. Mr. Coleman holds a B.S. degree in Applied Biology from the University of Rhode Island.

[gfp927z]

Neuro, I was wondering about the 'new chemistry' that has been patented since the arrival of Dr. Street earlier in the year. Since he was at Merck's Neuro Research in the UK for 20 years, I can't help but worry that some of his ideas for these new chemical structures may have come from there. If so, isn't there the potential for some type of patent infringement with Merck? Dr. Stoll has indicated that the new CX-1763, CX-1739 series of low impacts are in this 'new chemistry' group, and it also sounds like the recent 'breakthrough' in high impact technology also came upon Dr. Street's arrival.

Beyond the potential for patent trouble with Merck, since CX-1763 and CX-1739 are from a 'new chemistry' (perhaps non-benzamides?), there could be many surprises coming toxicologically. Cortex's previous compounds that have been advanced have all been from the well characterized benzamide class (Org-24448, CX-717, and most likely CX-701, all being benzofurazans).

[atheroprevent]

Wasn't Lynch's name mentioned by Stoll in conjunction with acquiring and broadening the U of Alberta RD patent. That process may have been completed, however, more than 90 days ago.

[gfp927z]

Neuro, >> Tran's signing on to me is a much more compelling indicator of belief in the company's prospects.<<

But Varney signed on to much acclaim right before the clinical hold hit, so a hiring is not necessarily predictive of a company's future prospects.

Pierre Tran's flip comments about the poor selection of food in Indianapolis as a factor in his employment decision also suggests that he may not be the driven, focused type that you'd ideally want as CMO. I may be biased though, after Cortex's experience with Servier.